In vivo  screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

Shaunna L. Beedie; Holly M. Rore; Shelby Barnett; Cindy H. Chau; Weiming Luo; Nigel H. Greig; William D. Figg; Neil Vargesson

doi:10.18632/oncotarget.8909

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

Shaunna L. Beedie _, Holly M. Rore, Shelby Barnett, Cindy H. Chau, Weiming Luo, Nigel H. Greig, William D. Figg and Neil Vargesson

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:33237-33245. https://doi.org/10.18632/oncotarget.8909

Metrics: PDF 2769 views | HTML 4043 views | ?

Abstract

Shaunna L. Beedie1,2, Holly M. Rore1, Shelby Barnett1,4, Cindy H. Chau2, Weiming Luo3, Nigel H. Greig3, William D. Figg2, Neil Vargesson1

1School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK

2Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA

3Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA

4Current address: Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, University of Manchester, Manchester, UK

Correspondence to:

William D. Figg, e-mail: [email protected]

Neil Vargesson, e-mail: [email protected], [email protected]

Keywords: angiogenesis, inflammation, thalidomide, cancer, teratogenesis

Received: September 21, 2015 Accepted: March 31, 2016 Published: April 22, 2016

ABSTRACT

Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8909

Publication Alerts

Post-Publication Promotion

Research Papers:

In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

Abstract